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Abstract
Background:  Graham Little – Piccardi – Lassueur (GLPL) syndrome is a rare dermatosis
characterized by scarring alopecia, loss of pubic and axillary hair, and progressive development of
variously located follicular papules. We report a first case ever of an autoimmune response in a
patient suffering from GLPL syndrome.
Methods: Immunofluorescence and immunoblot analysis were used in a variety of cell cultures
including human, monkey, hamster, mouse and bovine cells to analyze the presence of
autoantibodies in a GLPL patient.
Results:  The autoimmune serum showed a pattern of centromere and spindle microtubule
staining resembling that of the chromosomal passenger protein complex. By using a complex of
proteins expressed in baculovirus, immunoblot analysis demonstrated that the INCENP protein is
a major autoantigen in this patient with GLPL syndrome.
Conclusion:  An autoimmune response in GLPL syndrome is reported against the INCENP
centromere protein. The occasional development of autoimmunity in GLPL patients could serve as
a test in continuing efforts to detect this disease and for a more directed therapy based on the
autoantigen response.
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Background
The presence of cicatricial alopecia on the scalp, keratosis
pilaris on the trunk and extremities, and non-cicatricial
hair loss in the pubis and axillae was first described by Pic-
cardi in 1914 and a year later by Graham Little in a patient
sent by Lassueur. The GLPL syndrome is considered a
form of follicular lichen planus (LP), characterized by
lichenoid dermatosis, keratosis pilaris and progressive cic-
atricial alopecia of the scalp [1]. All the clinical manifesta-
tions need not to be present simultaneously. Association
with androgen insensitivity syndrome was also recently
described for GLPL Syndrome.
A familial case of occurrence in a mother and her daughter
was recently described with a HLA-DR1 in both patients
[2]. Topical or systemic corticosteroids, retinoids or PUVA
therapy are the treatments usually proposed and these
offer partial and temporary benefits [3]. More recently the
effectiveness of cyclosporin A was described for the first
time [4].
Immunofluorescence (IF) analysis is a common clinical
procedure used in studying the development and behav-
ior of several chronic diseases. Based on clinical features
and histological findings, we decided to perform an initial
IF test in a woman patient suffering GLPL syndrome.
Autoantibodies were found to recognize a mitotic-associ-
ated antigen which behaves like the previously-described
chromosomal passenger complex protein [5]. Our find-
ings represent the first report to date of an autoimmune
response in GLPL syndrome and this work, also allow us
to describe the first autoantibody directed to INCENP pro-
tein in humans. Further studies of the significance of
autoimmunity in GLPL patients will follow in the future.
Materials and methods
Human autoimmune serum
A 45 year old woman with alopecia in frontal area with
follicular hyperkeratosis and other clinical features was
diagnosed as suffering GLPL syndrome. Initial clinical test
by IF on standard human HEP2-fixed cells indicated pos-
itive antinuclear autoantibodies (ANAs) and specific mid-
body localization (data not shown). Anti SM, SSB, SSA,
CENP-B, Jo-1, ribosomal P, and histones were also ini-
tially determined negative by immunoblots.
Immunofluorescence analysis
Culture cells from hamster (CHO), monkey (CV1),
mouse (3T3) and bovine (MDBK) were grown on cover-
slips at 37°C in Dulbecco's modified Eagle's medium
(Gibco, Life Technologies Inc.) containing 7% fetal calf
serum. Cells were fixed in methanol for 10 min. at – 20°C
for autoantibody staining. The human GLPL serum was
used at 1:400 dilution in PBS for 45 min at 37°C followed
by 4 × 5 min time washes in PBS. FITC-conjugated goat
antihuman-Ig (Santa Cruz Lab. CA, USA) was used as a
second antibody at 1:100 dilutions in PBS for 45 min at
37°C. This was followed by 3 × 10 min washes in PBS.
Cells were counterstained for Hoechst and mounted in
PBS:glycerol 9:1. Staining was observed in a Zeiss epifluo-
rescent microscope and immunofluorescence images
were recorded by a CCD Spot Camera (Diagnostic Instru-
ments Inc. USA). For double indirect immunofluores-
cence microscopy, antibodies against Aurora B (Abcam),
INCENP (rabbit 1186), alfa-tubulin (Aldrich) and sec-
ondary antibodies coupled to FITC, Texas red or Cy5
(Jackson ImmunoResearch Laboratories) were used in
human U2OS cells following methods previously
described [6]. DNA was visualized with 0.5 ug/ml DAPI
and image stacks were captured using an Olympus micro-
scope controlled by DeltaVision SoftWorx (Applied Preci-
sion). Images were deconvolved and image stacks quick-
projected.
Cell extract, recombinant antigen preparation and 
immunoblot analysis
Whole cell extracts were prepared from HeLa culture cells
blocked with colcemid by lysis in SDS Laemmli buffer.
Three samples of 10/20/40 micrograms of protein were
loading on a gel. The cDNAs and baculovirus constructs
for Aurora B, Surviving, and INCENP have been previ-
ously described [7]. Insect Sf-9 cells were infected with
appropriate combinations of the constructs and com-
plexes containing GST-Aurora B, GST-INCENP, and His-
Survivin were purified on glutathione sepharose beads
(Amersham Biosciences) [8]. Cell extract and expressed
proteins were loaded in a 10% SDS-acrylamide gel and
transferred to nitrocellulose membranes (Millipore) in
the presence of Tris-HCl-glycine-SDS buffer [9]. The mem-
brane was blocked in 5% dried milk powder in PBS-0.1%
Tween for 2 hours at room temperature followed by incu-
bation with the human autoimmune GLPL serum at
1:200 dilution in PBS at room temperature for 12 hours.
Several washes in PBS-Tween were followed by reactivity
with a peroxidase-conjugated goat-anti human Ig (Sigma
Chemical Co, USA) diluted 1:3000 in PBS for 2 hours at
room temperature. The membrane was washed again for
3 × 10 min period in PBS-Tween and developed with 4-
chloro-1-naphthol (Sigma Chemical Co, USA) in PBS-
methanol-H2O2 until the color bands appeared. Rabbit
specific serum to INCENP protein [6] was assayed as a
control on blots with recombinant passenger protein
complex.
Results and Discussion
Cellular distribution of the GLPL syndrome autoantigen
In a routine clinical test by IF on standard HEP2 cells, the
Graham Little-Piccardi-Lassueur serum showed a mid-
body staining reminiscent of chromosome passenger pro-
teins (data not shown). To characterize in detail theJournal of Autoimmune Diseases 2007, 4:1 http://www.jautoimdis.com/content/4/1/1
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human autoimmune response, U2OS culture cells were
assayed by IF with GLPL serum showing a typical pattern
of staining in mitosis and interphase cells. During
prophase the autoantigen was found on the condensing
chromosomes, gradually becoming concentrated at the
centromeres [Figure 1B, GL]. This was evident in met-
aphase, where the autoantigen was localized at the centro-
meres apparently in all chromosomes [Figure 1C, GL].
During anaphase and telophase the staining was associ-
ated with microtubule bundles in the central spindle and
in the cleavage furrow as indicated by double staining
with anti-tubulin antibody [see details in white and red in
Figure 1D,E]. These IF patterns in human cells unequivo-
cally suggested to us that the GLPL serum presented reac-
tivity against a chromosomal passenger component and
this represented an autoimmune response in the patient.
This was corroborated by double IF staining with specific
anti-INCENP serum (green in Figure 1A–E). Further, to
clearly show that the GLPL autoantigen localizes like a
Chromosomal Passenger in human U2OS cells, four color
staining was performed with anti-Aurora B serum (green
in Figure 1E–F). Using this technology, unequivocally we
can clearly show in Figure 1, that the GLPL autoantigen
(red) co-localize with INCENP (white) and Aurora B
(green) proteins. The IF pattern observed was not
restricted to human cells, as shown in Figure 2. Culture
cells of different species showed a similar if not identical
IF staining pattern to those of human cells during all the
cell cycle stages. Some examples of IF localization
observed in hamster [Fig. 2a,b], mouse [Fig. 2c,d], bovine
[Fig. 2e,f] and monkey cells [Fig. 2g,h] are presented.
Identical IF patterns were found for the GLPL autoantigen
association to microtubule inter-chromosomal bundles
and midbody during cytokinesis in all the cell lines
assayed. This corroborated our initial hypothesis that the
autoimmune response in GLPL patient targeted several
components of the highly-conserved Chromosomal Pas-
senger complex already described from yeast to humans
[10].
INCENP protein is a major autoantigen in a GLPL 
syndrome patient
The next step in our study was to identify the GLPL
autoantigen by performing immunoblot analysis. First,
we used human whole cell extracts to test the reactivity of
the GLPL serum by western blots. As shown in Figure 3A,
the human autoantibody reacts in HeLa cell extracts with
a 135 kD polypeptide in a titration assay (lanes 1–3, Fig-
ure 3A). Similar result was observed in blots with CHO
cell extracts (data not shown), although other polypep-
tides of 91, 38, and 16 kd were also observed when the
blots were overexposed. Putatively, some of these
polypeptides represent the autoantigen(s) responsible for
the IF pattern observed in Figures 1 and 2. Based on these
IF results, we decided to test for reactivity of the GLPL
serum by immunoblot against a chromosomal passenger
protein complex. We used a protein extract (Figure 3B
lane 1) containing three of the major centromere passen-
ger proteins (INCENP, Aurora B and Survivin) expressed
in Sf9 culture insect cells by the baculovirus system [11].
The immunoblot clearly showed a strong reactivity (aster-
isk in Fig. 3B, lane 2) to the expected molecular weight for
the expressed INCENP component of the chromosomal
passenger complex (up arrow in Fig. 3B, lane1). No reac-
tivity was observed in the same blot against the other two
components of the complex present in the protein extract
(two lower arrows in Fig. 3B, lane1). A blot control against
the baculovirus expressed protein complex with a specific
anti-INCENP serum shows the mobility of the INCENP
protein component (asterisk in Fig. 3B lane 3). Figure 3,
clearly show that human GL autoantibody and anti-
INCENP serum recognized the same protein on blots.
From this result it can be concluded that INCENP protein
represents a major autoantigen in GLPL syndrome.
It is known that most of the anti-nuclear autoimmune
sera (ANAs) in humans are directed against macromolecu-
lar complexes of proteins or protein-nucleic acid struc-
tures [12]. The centromere per se is a target for
autoimmune diseases including scleroderma and CREST
syndrome [13], where the major centromeric autoanti-
gens described are CENP-A, CENP-B and CENP-C [14-16].
If the GLPL autoantibody used in this report also recog-
nizes some other centromere antigens in addition to the
INCENP protein, or some other component of the mitotic
machinery, is a possibility that could not excluded, and
more intensive experimentation will be required. Studies
by immunoprecipitation and screenings of expression
libraries are underway and could serve to test for that pos-
sibility.
INCENP is a major component of the centromere during
several phases of the mitotic cell cycle where it plays an
essential role in chromosome segregation and participates
in the mechanisms regulating mitosis [9,10]. Depletion of
INCENP by RNAi results in abnormal chromosome struc-
ture and defects in central spindle formation and cytoki-
nesis [5]. The relationship between autoimmunity against
INCENP and GLPL disease could be just fortuitous as for
many other autoimmune responses in humans. However
the levels of autoantibodies are good markers for moni-
toring the behavior of many human autoimmune diseases
[12].
The GLPL syndrome represents a rare disease and docu-
mentation is scarce [2,3]. Our report represents the first
evidence for autoimmunity in GLPL syndrome. By select-
ing a significant number of GLPL patients it may be possi-
ble to reach conclusions about the prevalence and clinical
significance of the autoimmune response in this disease.Journal of Autoimmune Diseases 2007, 4:1 http://www.jautoimdis.com/content/4/1/1
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Immunofluorescence of human cells with Graham Little autoimmune serum Figure 1
Immunofluorescence of human cells with Graham Little autoimmune serum. (A-E) localization of GL autoantigen in red and INCENP 
in green during interphase (A), prophase (B), metaphase (C), anaphase (D) and telophase (E). Anti-tubulin staining is shown in 
white and merge images with DNA in blue. GL autoantigen co-localizes with passenger protein INCENP in human U2OS cells. 
(F-G) Co-localization of GL autoantigen in red with INCENP in white and Aurora B in green at metaphase (F) and telophase 
(G). The merge images represent GL, Aurora B and DAPI. Scale bars 10 micro m.
GL INCENP α-tubulin DAPI
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Graham Little human autoantibody recognizes chromosomal passenger proteins in different mammalian cell lines Figure 2
Graham Little human autoantibody recognizes chromosomal passenger proteins in different mammalian cell lines. Staining of cells in 
anaphase (a, c, e, g) and midbody in cytokinesis (b, d, f, h) is shown for hamster (CHO in a-b), mouse (3T3 in c-d), bovine 
(MDBK in e-f) and monkey cells (CV-1 in g-h). The autoimmune serum reacts with conserved epitopes of passenger proteins in 
diverse species. Nuclei staining by Hoechst is shown in a'-h'.Journal of Autoimmune Diseases 2007, 4:1 http://www.jautoimdis.com/content/4/1/1
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